|
Xin
Zhou1, Yuan Xin Li2, Ning Li2 and Jie Shou Li2
1Department
of General Surgery, Medical School, Nanjing University, Nanjing
210093, Jiangsu Province, China
2Research Institute of General Hospital, Chinese PLA
General Hospital of Nanjing Military Area, Nanjing 210002, Jiangsu
Province, China
Xin Zhou, graduated from Medical School of Nanjing University in
1998, now a doctoral candidate of Nanjing University, majoring
general surgery.
Supported partially by the Medical and Health Research Foundation of
PLA, No. 98Q015
Correspondence to Xin Zhou, Research Institute of General
Surgery, Chinese PLA General Hospital of Nanjing Military Area,
305 East Zhongshan Road, Nanjing 210002, Jiangsu Province, China
Telephone:
0086-25-3387871 Ext.58088, Fax. 0086-25-4803956
Received: 2000-09-21 Accepted:
2000-11-20
Zhou
X, Li YX, Li N, Li JS. Effect of bowel rehabilitative therapy on
structural adaptation of remnant small intestine: animal experiment.
World J Gastroentero, 2001;7(1):66-73
Subject
headings:
short bowel syndrome; intestinal mucosa; somatotropin; glutamine;
dietary fiber; parenteral nutrition, total; rats
Abstract
AIM :To investigate the individual and the combined effects
of glutamine, dietary fiber, and growth hormone on the structural
adaptation of the remnant small bowel.
METHODS: Forty-two adult male Sprague-Dawley rats underwent
85% mid-small bowel resection and received total parenteral
nutrition (TPN) support during the first three postoperational days.
From the 4th postoperational day, animals were randomly assigned to
receive 7 different treatments for 8 days: TPNcon group, receiving
TPN and enteral 20g.L-1 glycine perfusion; TPN+Gln group,
receiving TPN and enteral 20g.L-1 glutamine perfusion;
ENcon group, receiving enteral nutrition (EN) fortified with 20g·l-1
glycine; EN+Gln group, enteral nutrition fortified with 20g.l-1
glutamine; EN+Fib group, enteral nutrition and 2g.l-1
oral soybean fiber; EN+GH group, enteral nutrition and subcutaneous
growth hormone (GH) (0.3IU) injection twice daily; and ENint group,
glutamine-enriched EN, oral soybean fiber, and subcutaneous GH
injection.
RESULTS: Enteral glutamine perfusion during TPN increased the
small intestinal villus height (jejunal villus height 250µm±29µm
in TPNcon vs 330µm±54µm in TPN+Gln, ileal villus height 260µm±28µm
in TPNcon vs 330µm±22µm in TPN+Gln, P<0.05) and mucosa
thickness (jejunal mucosa thickness 360µm±32µm in TPNcon vs 460µm±65µm
in TPN+Gln, ileal mucosa thickness 400µm±25µm in TPNcon vs 490µm±11µm
in TPN+Gln, P<0.05) in comparison with the TPNcon group. Either
fiber supplementation or GH administration improved body mass gain
(end body weight 270g±3.6g in EN+Fib, 265.7g±3.3g in EN+GH, vs
257g±3.3g in ENcon, P<0.05), elevated plasma insulin-like growth
factor (IGF-I) level (880µg·l-1±52µg.l-1 in
EN+Fib, 1200µg·l-1±96µg·l-1 in EN.GH, vs
620µg·l-1±43µg·l-1 in ENcon, P<0.05),
and increased the villus height (jejunum 560µm±44µm in EN.Fib,
530µm±30µm in EN.GH, vs 450µm±44µm in ENcon, ileum 400µm±30µm
in EN+Fib, 380µm±49µm in EN.GH, vs 320µm±16µm in ENcon,
P<0.05) and the mucosa thickness (jejunum 740µm±66µm in EN.Fib,
705µm±27µm in ENGH, vs 608µm±58µm in ENcon, ileum 570µm±27µm
in EN.Fib, 560µm±56µm in EN.GH, vs 480µm±40µm in ENcon, P<0.05)
in remnant jejunum and ileum. Glutamine-enriched EN produced little
effect in body mass, plasma IGF-I level, and remnant small bowel
mucosal structure. The ENint group had greater body mass (280g±2.2g),
plasma IGF-I level (1450µg·l-1±137µg·l-1),
and villus height (jejunum 620µm±56µm, ileum 450µm±31µm) and
mucosal thickness (jejunum 800µm±52µm, ileum 633µm±33µm) than
those in ENcon,EN+Gln (jejunum villus height and mucosa thickness
450µm±47µm and 610µm±63µm, ileum villus height and mucosa
thickness 330µm±39µm and 500µm±52µm), EN+GH groups
(P<0.05), and than those in EN+Fib group although no statistical
significance was attained.
CONCLUSION: Both dietary fiber and GH when used separately
can enhance the postresectional small bowel structural adaptation.
Simultaneous use of these two gut-trophic factors can produce
synergistic effects on small bowel structural adaptation. Enteral
glutamine perfusion is beneficial in preserving small bowel mucosal
structure during TPN, but has little beneficial effect during EN.
INTRODUCTION
Various clinical conditions necessitate therapeutic massive small
bowel resection, which is often followed by serious malabsorption,
characterized by intractable diarrhea, steatorrhea, and weight loss.
This malabsorptive state is defined as short bowel syndrome.
Traditionally, parental nutrition (PN) is prescribed for these
patients to assure adequate nutritional status and obtain enough
time to wait for the remnant small bowel to undergo adaptation, with
the hope of eventual transition from parental nutrition support to
volitional enteral nutrition. Under this supportive therapeutic
strategy, however, some patients may never achieve complete
adaptation, i.e., sustaining completely on enteral nutrition, and
life long total parental nutrition (TPN) become lifesaving unless
successful small bowel transplantation is conducted[1-3].
Unfortunately, long-term TPN is associated with great expense,
vitamin or trace element malnutrition, recurrent catheter sepsis,
and progressive cholestatic liver disease[4],
whereas small bowel transplantation is still used currently as a
salvage therapy for patients with severe metabolic complications,
hepatic failure, or lack of venous access due to imperfect
management of post transplantational rejection[5].
Therefore,
any therapy aimed at actively accelerating or enhancing the adaptive
process in the residual bowel is likely to impact greatly on the
patients'
life style and the costs of
medical care. Since 1995 Byrne et al have published a series
of studies, which demonstrated that a combination of growth hormone,
glutamine, and modified fiber-enriched diet can improve nutrient
absorption, decrease stool output, and reducte TPN requirement[6-8].
These reports are the first to introduce the concept that further
bowel adaptation can occur with the use of specialized nutrients and
growth factors, and ushered in a new era in the treatment of short
bowel syndrome. However, many questions about this therapy are to be
answered, e.g., whether this therapy has enhanced the structural
adaptation in the remnant small bowel and how each component of the
remedy contributes to bowel adaptation.
Due
to the heterogeneity in patient age, underlying diseases, and
anatomy of the remnant bowel as well as ethic concerns, it is rather
difficult to answer these questions directly from the patients.
Consequently, we conducted this animal experiment in an attempt to
assess the individual and combined effect of glutamine, dietary
fiber and growth factor on the structural small bowel adaptation
immediately after massive small bowel resection.
MATERIALS AND METHODS
Animals and surgical procedures
The animal protocols and procedures were approved by the Laboratory
Animal Medicine Ethics Committee of Nanjing Military Area General
Hospital of Chinese PLA. Male Sprague Dawley rats weighing between
220g and 250g (Shanghai Laboratory Animals Center, Chinese Academy
of Sciences) were allowed 1 week to get acclimatized to our
laboratory conditions before surgery. They were kept in individual
stainless steel cages and fed a standard rat chow with free access
to tap water in a room maintained at 22℃
on a 12h day/night cycle (06:00/18:00).
The
animals weighed about 260g to 290g at the end of acclimation period,
and were fasted for 12 hours before surgery. Surgical procedures
were performed using aseptic technique under anesthesia by
intramuscular ketamine cocktail (ketamine, 100mg·kg-1;
and xylazine 8mg·kg-1). Three surgeries were performed
on each animal in the following sequence: placement of TPN catheter
in the superior vena cava via the external jugular vein,
installation of gastrotomy tube for liquid diet delivery, and 85%
mid-small bowel resection. Both tubes were tunneled subcutaneously,
and the dorsal cervical region exited through a spring-swivel
apparatus. Normal saline was administered at 1mL·h-1
through the TPN catheter with a minipump. Small bowel resection left
the first 6cm jejunum from the Treitz ligament and the terminal 6cm
ileum. The day when operations were performed was dated as day 0.
The postoperative days were dated as day n.
Experimental design
After the operation, animals were placed back to stainless steel
cages and supported with total parenteral nutrition (TPN), the
composition of which is indicated in Table 1. TPN was administered
at a half-rate of 1.25mL·h-1 on day 1, and full rate of
2.5mL·h-1 on day 2 and 3. From day 4, animals were
randomly allocated to seven experimental groups: ENcon group,
receiving control liquid enteral nutrition (EN); EN+Gln group,
receiving EN enriched with 20g·L-1 glutamine; EN+Fib
group, receiving control EN and fed with 2g/d soybean fiber,
containing 70% total dietary fiber (provided by Nanjing Military
Area General Hospital of Chinese PLA, Nanjing, China), and was mixed
with water to the consistency of porridge; EN+GH group, injected
with control EN and 0.3IU recombinant human growth hormone (rhGH) (Saizen,
provided by Laboratories Serona S.A., 1170 Aubonne, Switzerland)
subcutaneously twice a day; ENint group, receiving subcutaneous
injection of EN enriched with 20g·L-1 glutamine, 2g·d-1
soy bean fiber, and 0.3IU rhGH twice a day; TPNcon group, receiving
TPN, and 20g·L-1 glycine perfusion via gastrotomy
tube; and TPN+Gln group, receiving TPN, and 20g·L-1 glutamine
perfusion via gastrotomy tube. Each experimental group
contained 6 animals. The liquid EN was fiber free with the
compositions as indicated in Table 2, and was reconstituted with
sterile water before perfusion and used within 12 hours to avoid
bacteria growth. Gastrotomy tube feeding of EN or amino acid
solution was introduced gradually by the following schedule:
half-strength solution at 1.25mL·h-1 on day 4, full
strength solution at 1.25mL·h-1 on day 5, and
full-strength solution at 2.5mL·h-1 from day 6-until day
12. PN was continued until full strength EN was administered at
full-rate, thus combined EN and PN to supply 251kJ calorie to the
animals. Our formulas for TPN and EN supplied isocaloric and
isonitrogenous nutrition to all animals, i.e., 251Kj nonprotein
calories, 0.414g nitrogen from PN or Pepti 2000 variant, and 0.272g
nitrogen from glutamine enrichment or glycine for control per day
for each animal. Glutamine enrichment constituted 39.5% of the total
nitrogen. Water was provided ad lib throughout the study.
Table 1 Total parenteral nutrition composition (400mL)
|
Ingredients
|
mL
|
|
500g·L-1
glucose
|
100.0
|
|
Fat
(300g·L-1 intralipid *)
|
67.5
|
|
Amino
acid (114g·L-1 Novamin *)
|
150.0
|
|
100g·L-1
NaCl
|
10.0
|
|
100g·L-1
KCl
|
10.0
|
|
100g·L-1
calcium gluconate
|
5.0
|
|
Multi-electrolytes
(Addemel *)
|
2.5
|
|
Water-soluble
vitamins (Soluvit *)
|
2.5
|
|
Lipid-soluble
vitamins (Vitalipid *)
|
2.5
|
|
Nonprotein
energy (kJ·mL-1)
|
4.2
|
|
Total
nitrogen (g)
|
2.7
|
|
NPC/N
(kJ·g-1)
|
620
|
*Provided
by Sino Swed Pharmaceutical Corp. Ltd., Wuxi, China. NPC/C:
nonprotein energy per gram of nitrogen.
Table 2 Enteral nutrition composition (420mL)
|
Ingredients
|
Control
EN
|
Glutamine
enriched EN
|
|
Pepti-2000
variant * (g)
|
126.0
|
126.0
|
|
Protein
hydrolysate (g)
|
19.9
|
19.9
|
|
Nitrogen
(g)
|
2.9
|
2.9
|
|
Fat
(g)
|
4.9
|
4.9
|
|
Vegetable
(g)
|
2.45
|
2.45
|
|
MCT
(g)
|
2.45
|
2.45
|
|
Linoleic
acid
|
1.12
|
1.12
|
|
Carbohydrates
(g)
|
93.1
|
93.1
|
|
Malto
dextrin (g)
|
91.7
|
91.7
|
|
Lactose
(g)
|
<1.12
|
<1.12
|
|
Organic
acid (g)
|
0.01
|
0.01
|
|
Minerals
(g)
|
2.6
|
2.6
|
|
Vitamins
(g)
|
0.4
|
0.4
|
|
Glycine
(g)
|
10.0
|
0
|
|
Glutamine
(g)
|
0
|
10.0
|
|
Nonprotein
energy (kJ·mL-1)
|
4.2
|
4.2
|
|
NPC/N
|
610
|
610
|
*A
commercial, nutritional complete, short-chain peptide based
elemental diet (Nutricia, the Netherland). NPC/N: nonprotein energy
per gram of nitrogen from Pepti-2000 variant.
Plasma and tissue isolation
Body mass was monitored every three days after surgery as an index
of nutritional status. At about 12:00 am on the 12th postoperative
day, laparotomy was performed on all animals under anesthesia with
ketamine hydrochloride (100mg·kg-1) . Blood was obtained
from the inferior vena cava and placed on ice in a heparin
pretreated tube. Plasma was then isolated by centrifugation at 4℃
and stored at -20℃
for later analysis.
The
residual small intestine was rapidly resected from peritoneal and
vascular connections, and the luminal content was removed. After the
intestine was flushed with ice cold normal saline, 2cm segments from
both jejunum and ileum located between 2 and 4cm from the
anastomosis were removed and fixed in phosphate buffered neutral
formalin. The animals were then killed by exsanguination.
Plasma insulin-like growth factor (IGF-Ⅰ)
assay and histological image analysis
Total plasma IGF-Ⅰ
concentrations were measured after acid-ethanol extraction with the
rat IGF-Ⅰ
RIA DSL-2900 kit (Diagnostic Systems Laboratories, Inc., Webster,
USA) in duplication, following the instruction of the manufacturer.
This measurement was taken both as indicator of nutritional status
and evidence of rhGH treatment.
Villus
height (from villus base to villus tip), crypt depth (from crypt
base to villus base), and mucosal thickness (from crypt base to
villus tip) were taken as indicators of structural adaptation.
Routine hematoxylin and eosin stained sections were prepared, and
HPIAS 1000 True Color Image Analysis System (Tongji Qianping Image
Engineering Corp., Wuhan, China) was employed to analyze the image.
Fifteen intact axially oriented villi and crypts selected from each
specimen were measured.
Statistical analysis
Data were expressed as x-±s. Multiple comparison tests were
performed after analysis of variance with the Student-Newman-Keuls
test. Differences with P value less than 0.05 were considered
to be statistically significant.
RESULTS
Body mass
As shown in Table 3 and Figure 1, the initial body mass on day 0 was
similar among the 7 experimental groups. The body mass on day 3 was
not significantly different among the 7 groups, which reflected
similar operative stress and postoperative nutritional support
remedy. The overall body mass loss during the first three
postoperative days averaged 26.3g. Marked body mass difference was
evident from day 6. The two TPN-supported groups had gained
remarkable body mass by day 6 which was kept steady during the
remainder of the experimental period, suggesting the ebbing of
stress and fixed nutrition supply. No significant body mass
difference was observed between the two TPN groups throughout the
experiment. In ENcon, EN+Gln, and EN+GH groups, the introduction of
EN resulted in further body mass loss, which was accompanied by a
moderate to a large amount of liquid stool production, indicating
insufficient nutrition assimilation from the remnant small bowel.
From day 6, diarrhea in these groups became increasingly milder and
almost disappeared after day 9, which was associated with gradual
body mass gain. Each animal in two fiber-supplied groups ate up
daily fiber supply, and fiber-containing solid stool instead of
large liquid stool was observed after EN introduction. Continuous
body mass gain began from day 3 in ENint group, and after day 6 in
EN+Fib group. From day 3, the mean body mass of ENint group
maintained higher than those of the other groups, which bore
statistical significance on day 6 when compared with ENcon, EN+Fib,
and EN+GH groups, and on day 9 and day 12 when compared with TPNcon,
ENcon, EN+Fib, and EN+GH groups. Throughout the study, ENcon and
EN+Gln groups had similar body mass, which remained significantly
lower than that of TPNcon on day 6 and day 9 and rose to the similar
level as TPNcon on day 12. From day 6, mean body mass of EN+Fib
groups began to distinguish itself significantly from ENcon, and
became markedly higher than both ENcon and TPNcon on day 12. On day
9, the mean body mass of EN+GH groups was significantly higher than
that in ENcon group, and on day 12 significantly higher than both
ENcon and TPNcon groups.
Figure 1(PDF)
Body mass before and after surgery.
aP<0.05,
vs TPNcon; bP<0.05,
vs ENcon; cP<0.05,
vs EN+GH; dP<0.05,
vs EN+Fib. Day 0, refers to the day operation was performed, from
which the time was dated.
Plasma IGF -Ⅰ
concentrations
Plasma IGF-Ⅰ
concentrations were similar among TPNcon, TPN+Gln, ENcon, and EN+Gln
groups. Plasma IGF-Ⅰ
level in EN+fib group was significantly higher than that in ENcon
group. GH treatment resulted in significant increase in plasma IGF-Ⅰ
concentration as compared with ENcon group. ENint group had the
highest level of plasma IGF-Ⅰ(Figure
2).
Figure 2
Plasma insulin-like growth factor level on day 12.
aP<0.05,
vs Encon; bP<0.05,
vs EN+Fib; cP<0.05,
vs EN+GH.
Remnant intestinal mucosal structure
Compared with ENcon group, TPNcon group had significantly lower mean
villus height and mucosal thickness in both remnant jejunum and
ileum, and significantly shallower jejunal crypt (Figures 3 and 4).
Luminal glutamine perfusion completely restored the villus height
and mucosal thickness in ileum and partially restored the villus
height, crypt depth, and mucosal thickness in jejunum. However,
glutamine-enriched EN had a little impact on mucosal structural
parameters whether in remnant jejunum or ileum when compared with
ENcon group. The villus height and mucosal thickness in both remnant
jejunum and ileum were more significantly increased by fiber
supplementation than in ENcon group. GH treatment produced
significant increase in villus height in both remnant jejunum and
ileum, and mucosal thickness in remnant ileum when compared with
ENcon group. Combined treatment with glutamine, fiber, and GH
significantly deepened the crypt in remnant ileum as against TPNcon
group, and further increased villus height and mucosal thickness in
both remnant jejunum and ileum, which, when compared with EN+GH
group, achieved statistical significance in villus height of both
jejunum and ileum, and in mucosal thickness of ileum.
Table 3 Comparison of body mass before and after operation
between each experiment groups (n=6, x-±s, g)
|
Groups
|
Day
0
|
Day
3
|
Day
6
|
Day
9
|
Day
12
|
|
TPNcon
|
276.3±9.0
|
247.8±7.4
|
255.5±3.6
|
256.8±3.4
|
257.3±2.9
|
|
TPN+Gln
|
277.0±6.1
|
249.7±6.5
|
256.7±4.0
|
258.7±3.7
|
259.3±2.9
|
|
Encon
|
278.8±7.8
|
251.2±8.0
|
244.7±3.2a
|
250.7±3.5a
|
257.3±3.3
|
|
EN+Gln
|
279.8±8.9
|
251.8±7.1
|
246.5±3.4a
|
252.8±2.7
|
258.0±2.5
|
|
EN+fib
|
280.5±8.0
|
253.8±6.6
|
252.2±2.0b
|
261.8±3.4b
|
270.7±3.6a,b
|
|
EN+GH
|
278.7±12.9
|
255.7±6.2
|
247.8±2.3a
|
257.5±3.3b
|
265.7±3.3a,b
|
|
ENint
|
278.8±8.1
|
255.5±6.2
|
260.5±2.4b,c,d
|
272.7±2.3a,b,c,d
|
280.5±2.2a,b,c,d
|
aP<0.05,
vs TPNcon; bP<0.05,
vs ENcon; cP<0.05,
vs EN+Fib; dP<0.05,
vs EN+GH. Day 0, refers to the day operation was performed, from
which the time was dated.
Figure 3(PDF)
Crypt depth, villus height and mucosal thickness of the remnant
ileum.
aP<0.05,
vs TPNcon; bP<0.05,
vs ENcon; cP<0.05,
vs EN+GH.
Figure 4(PDF)
Crypt depth, villus height and mucosal thickness of the remnant
jejunum.
aP<0.05,
vs TPNcon; bP<0.05,
vs ENcon; cP<0.05,
vs EN+GH.
DISCUSSION
After massive small bowel resection, the structural adaptation
of the remnant small bowel was characterized by mucosal hyperplasia.
The villus height and crypt depth are both increased, while cell
hypertrophy is considered unimportant[9].
This process is influenced by many factors, among which, both the
quantity and route of nutrient intake are important regulators.
Luminal nutrient supply, which is essential for structural
adaptation, serves as not only energy source, but also signal for
endogenous secretions and the release of various gut trophic
hormones and growth factors. On the other hand, normal nutritional
status, which usually needs the facilitation of TPN to maintain,
favors bowel adaptation[1].
In this study, great efforts were made to ensure strict control on
the quantity and route of nutritent supply, and TPN was used
immediately after bowel resection and during the period of
reintroduction of enteral nutrition to improve the nutritional
status. The compositions and delivery schedules for TPN and EN were
set to provide isocaloric and isonitrogenus nutrition and to produce
comparable overall nutritional status in animals of each
experimental group. And the goal of producing comparable nutritional
status was attained, which was attested by similar body mass and
plasma total IGF-Ⅰ
concentration among TPNcon, TPN+Gln, ENcon, and EN+Gln groups. The
utilization of plasma IGF-Ⅰ
as index of nutritional status is justified by sensitive IGF-Ⅰ
response to dietary intake, close correlation with body composition,
short half-life, and its nycthermeral stability[10].
Thus the risk of confounding effects of variation in nutritional
supplementation had been minimized.
Substantial
researches have been done to modify the formulation of enteral
nutrition to optimize the postresectional small bowel adaptation.
Pepti-2000 variant has often been recommended as fiber-free EN to
patients with short bowel syndrome in Nanjing Military Area General
Hospital of Chinese PLA and has been chosen in this experiment as
the EN formulation. This is justified by its compositional feature
as peptide-based, polymeric nutrient complete diet, which provide
equal energy from medium-chain triglycerides and long-chain
triglycerides. Polymeric diets are more trophic for intestinal
adaptive hyperplasia compared with monomeric diets. Partial
hydrolysation or protein facilitates amino acid absorption from
peptide transporters while preserves gut trophic effect.
Medium-chain triglycerides are water-soluble and are better absorbed
in the presence of bile acid or pancreatic insufficiency, while
long-chain triglycerides are more effective in inducing adaptation[11].
Glutamine
is an essential nutrient for intestinal mucosa. Besides serving as
the structural unit of protein synthesis, a precursor for synthesis
of nucleotides and other micromolecules, it is the major respiratory
fuel for intestinal mucosa[12].
In vitro studies have indicated that intracellular mitogenic
signal transduction can be modified by glutamine supply and
metabolism[13].
Animal studies have consistently shown that total parenteral
nutrition (TPN) induced intestinal hypoplasia can be attenuated by
parenteral glutamine supplementation[14-16].
Glutamine-fortified-parent-eral or enteral nutrition has also been
demonstrated to accelerate small intestinal healing and improves
survival outcome after chemotherapy and radiation[17,18].
Following
massive bowel resection, malabsorption occurs and patients may be
intolerable to enteral nutrition and have to sustain on TPN for a
certain period. Efforts made to preserve intestinal mucosal mass and
absorption area during TPN will assist early reintroduction of
enteral nutrition, which is essential for the initiation of
intestinal adaptation. Parenteral glutamine supplementation has been
shown to prevent TPN induced mucosal atrophy in the remnant small
intestine after 85% resection[19].
Since enteral glutamine can be readily absorbed by small intestinal
epithelium, and glutamine oxidation stimulates enterocyte Na +/H +
exchange, leading to a high rate of electroneutral NaCl absorption
in healthy and diseased jejunum[20],
we studied the effect of enteral glutamine perfusion on the remnant
intestinal mucosal structure during TPN. Because previous studies
have not confirmed the beneficial effect of enteral glutmine
supplementation during EN[21-25],
we also studied the effect of adding extra glutamine to
nutrition-complete enteral diet. Our results confirmed the existence
of TPN induced intestinal hypoplasia, which was indicated by
significantly lower villi in both jejunum and ileum and markedly
shallower crypts in jejunum in TPNcon group compared with ENcon
group. Luminal glutamine perfusion was effective to reverse TPN-induced
hypoplasia in ileum and partially reverse TPN-induced hypoplasia in
jejunum. In contrast, glutamine-supplemented enteral nutrition has
little impact on small intestinal structural parameters. This
finding is surprising, yet is similar to the results of several
other studies[19-23].
The dosage ranged approximately from 2g·kg-1·day-1
to 5.6g·kg-1·day-1. And a dosage of more
than 4g·kg-1·day-1 was found effective in
preventing TPN induced intestinal hypoplasia in rats[12].
In all these studies, glutamine-fortified enteral nutrition was
compared with standard rat chow or non-glutamine-containing
elementary diet, or EN with insufficient glutamine due to partial
hydrolysation of protein. Therefore, the lack of effect cannot be
interpreted as insufficient glutamine delivered to intestine, or
overload of glutamine. Different routes of administration were
tried. Extra glutamine was mixed with enteral diet to form ad lib
diet, or was administrated separately in bolus form, or administered
as 24h continuous enteral perfusion. The remnant intestines were
analyzed 2, 7, 14 or 21 days after small bowel resection. The time
points represent the beginning, active, and maximal remnant
intestinal hyperplasia. In most of those studies, the animals gained
body mass. In our study, the animals maintained the body mass lower
than that of preoperation, reflecting our restrict nutrition supply.
Nevertheless, despite different experimental protocols, similar
results were obtained that during enteral nutrition, enteral
glutamine supplementation produced little effect on remnant small
intestinal morphological parameters. Therefore, the current
available data raise the hypothesis that for otherwise healthy small
intestine, with adequate enteral nutrition stimulation, glutamine
delivered by arterial blood is sufficient for optimal intestinal
growth. In consistent with this hypothesis, in vitro studies
have shown that in a number of cell lines, maximal proliferation
occurs when glutamine concentrations are maintained at 0.5mmol·L-1
or above, a concentration approximates normal plasma concentration[26].
With the maximal mitogenic stimulation of epidermal growth factor,
the optimal proliferation of IEC-6, a rat jejunum cell line,
occurred at a glutamine concentration of 1.0mmol·L-1 in
the cultural medium, a concentration within the physiologic ranges
of glutamine found in rat plasma[27].
Under normal nutritional status, plasma glutamine homeostasis can be
maintained without nutritional glutamine supply[28].
However, in the absence of luminal nutrition stimulation during TPN,
glutamine delivered by blood flow may be insufficient for optimal
intestinal growth, as is attested by the fact that parenteral or
enteral glutamine supplementation is effective in reducing TPN-induced
intestinal hypoplasia. This insufficiency may be caused by decreased
blood flow induced by TPN, or enteral nutrition can stimulate the
uptake of glutamine through the basolateral membrane by modifying
the activity of the transporters. However, our data do not exclude
the possibility that when inadequate enteral nutrition is received,
enteral glutamine may exert a trophic effect on small intestine,
since minimum luminal nutrition has been found indifferent in
stimulating small intestinal mucosal growth as compared
with TPN[29].
Dietary
fiber includes a wide variety of carbohydrates that, as a group, are
resistant to enzymatic hydrolysis within the human gastrointestinal
tract. The principal physiologic function of dietary fiber are
regulating gastric emptying and intestinal transit time, based on
the bulking action of the fiber. Insoluble fibers are minimally
fermented and function almost solely as bulking agents that decrease
colonic transit time and increase fecal mass. Soluble fibers are
largely fermented by anaerobic gut flora, resulting in increase of
the bacterial quantity, and fecal mass, and production of short
chain fatty acids (SCFAs), which are quickly absorbed by the colonic
mucosa. The importance of dietary fiber in maintenance of normal
colonic morphology and function has been widely acknowledged.
However, its role in short bowel syndrome has not been investigated
thoroughly. Previous studies on the effect of dietary fiber on colon
were mostly carried out in normal animals with intact small and
large intestine. In contrast, after massive small bowel resection,
the colon in continuity with the remnant small bowel will receive
substantial unabsorbed carbohy drates and protein, which will
undergo fermentation in colon by various anaerobic bacteria and
produce SCFAs. This represents an important mechanism whereby the
colon compensates some energy absorption function of the lost small
intestine[30,31].
How colon with this altered environment responses to additional
dietary fiber loading is not clear. Although there is the
speculation that in carbohydrates malabsorption, dietary fiber
supplementation seemed to be redundant in enhancing the SCFAs
production[11],
available data from massive small bowel resection models showed the
beneficial effect of dietary fiber supplementation on residual small
bowel as well as colon adaptation[32-34].
In contrast, dietary fiber had little effect on intact intestinal
function[35].
Therefore, it seems that the effect of dietary fiber is modified by
the absorptive function of intestine.
We
fed the animals with fiber free enteral nutrition of 2g soy bean
fiber daily, containing about 70% total dietary fiber consisting
predominantly of insoluble fiber, and found that soy bean fiber
supply led to large solid fiber-containing stool, instead of large
liquid stool as seen in non-fiber supplied EN groups. This indicates
that fiber supply may alter the colon absorptive and moving
function. Significantly improved body mass recovery was associated
with this improved stool consistency. In addition, the plasma IGF-Ⅰ
concentration was simultaneously elevated, which implied that the
improved body mass was not solely caused by colonic fiber retention.
Both the residual jejunum and ileum displayed significantly greater
mean villus height and mucosal thickness. The exact mechanism that
soybean fiber enhanced the postresectional adaptation was not
investigated in this study. Since the soy bean fiber consisted
predominantly of insoluble fiber which mainly influences the
intestinal transit, it is most likely that the presence of fiber in
combination with unabsorbed carbohydrates and proteins in the colon
had delayed the intestinal transit through direct bulk effect, hence
promoting the colonic fermentation of unabsorbed carbohydrate and
protein. Consequently, the secretion of colon-derived enteric
hormones, such as enteroglucagon and peptide YY, might be augmented,
which in turn exerted their small bowel trophic effect and
stimulated further structural adaptation in small bowel.
Besides
gut-special nutrients such as glutamine and dietary fiber, the
possible role of many growth factors has met with intense research
interest. Strong evidence has demonstrated that growth hormone (GH)
is an important growth factor for intestine. Complete GH depletion
due to hypophysectomy caused pronounced hypoplasia of small
intestinal mucosa with decreased villus height and reduced crypt
cell proliferation[36].
Simple replacement of GH can restore mucosal proliferative activity[37].
The study of the transgenic mice overexpressing the bovine growth
hormone demonstrated that chronic excessive GH can produce
hyperplasia in small intestinal mucosa whether food intake was ad
lib or restricted[38].
Hypophysectomy could impair the adaptive hyperplasia in response to
small bowel resection[39].
In an unpaired fed study, exogenous GH was found to enhance mucosal
hyperplasia after extensive small bowel resection[40].
Our pair-fed study revealed that exogenous GH administration
significantly elevated the plasma IGF-Ⅰ
level, increased villus height in both remnant jejunum and ileum,
and significantly increased ileum mucosal thickness. Postresectional
body mass recovery was also accelerated by GH administration,
suggesting the enhanced nutrient absorption. Our data further
confirmed the gut-trophic property of GH. The more important
findings of our study are that concomitant fiber supplementation
further enlarged the villus height and mucosal thickness in both
remnant ileum and jejunum, enhanced body mass gain, and increased
the plasma IGF-Ⅰ
concentration in ENint group. These results suggest that gut trophic
growth factor, GH, can be used in combination with gut-special
nutrient, dietary fiber, to bring about synergistic effect on
postresectional remnant small bowel structural adaptation.
In
summary, our study demonstrated that both dietary fiber and growth
hormone can enhance the postresectional small bowel structural
adaptation, promote bodymass gain, and increase plasma IGF-Ⅰ
level when used separately. Simultaneous use of these two gut-trophic
factors produced synergistic effect on structural adaptation
parameters, body mass, and plasma IGF-Ⅰ
concentration. In contrast, the gut essential nutrient, glutamine
when enterally administered with enteral nutrition, showed little
beneficial effect on remnant small bowel structural adaptation, and
the body mass did not alter in comparison with the control enteral
nutrition. However, enteral glutamine is effective in preserving
intestinal mucosal structure during TPN. These findings raise the
doubt about the necessity of enteral glutamine supplementation
during enteral nutrition. On the other hand, they provide the
evidence favoring the combined utilization of GH and dietary fiber
with enteral nutrition in patients with short bowel syndrome.
REFERENCES
1 Li N, Li
JS, Liao CX, Li YS. Antirejection therapy with Tripterygium
woifordii and low-dose cyclosporine in small bowel
transplantation
in pigs. China Natl J New Gastroenterol, 1996;2:36-40
2 Li YS, Li
JS, Li N, Jiang ZW, Li YX, Li XH. Endoscopic monitoring in small
bowel transplantation. China Natl J New
Gastroenterol,
1997;3:137-138
3 Li YS, Li
JS, Li N, Jiang ZW, Zhao YZ, Li NY, Liu FN. Evaluation of various
solutions for small bowel graft preservation.
World
J Gastroenterol,1998;4:140-143
4 Liang LJ,
Yin XY, Luo SM, Zheng JF, Lu MD, Huang JF. A study of the
ameliorating effects of carnitine on hepatic
steatosis
induced by total parenteral
nutrition in rats. World J Gastroenterol, 1999;5:312-315
5 Wilmore
DW, Byrne TA, Persinger RL. Short bowel syndrome: New therapeutic
approaches. Curr Probl Surg,
1997;34:389-444
6 Byrne TA,
Morrissey TB, Nattakom TV, Ziegler TR, Wilmore DW. Growth hormone,
glutamine, and a modified diet
enhance
nutrient absorption in patients with severe short bowel
syndrome. JPEN, 1995;19:296-302
7 Byrne TA,
Persinger RL, Young LS, Ziegier TR, Wilmore DW. A new treatment for
patients with short-bowel syndrome.
Ann
Surg, 1995;222:243-255
8 Wilmore
DW, Lacey JM, Soultanakis RP, Bosch RL, Byrne TA. Factors predicting
a successful outcome after
pharmacologic
bowel compensation. Ann Surg, 1997;226:288-293
9 Williamson
RCN, Chir M. Intestinal adaptation. Structural, functional and
cytokinetic changes. N Eng J Med,
1978;298:1393-1402
10 Thissen JP, Ketelslegers JM, Underwood LE. Nutritional
regulation of the insulin-like growth factors. Endocr Rev,
1994;15:80-101
11 Vanderhoof JA, Langnas AN. Short-bowel syndrome in children
and adults. Gastroenterology, 1997;113:1767-1778
12 Souba WW, Smith RJ, Wilmore DW. Glutamine metabolism by the
IntestinalTract. JPEN, 1985;9:608-617
13 Rhoads JM, Argenzio RA, Chen W, Rippe RA, Westwick JK, Cox
AD, Berschneider HM, Brenner DA. L-Glutamine
stimulates
intestinal cell proliferation and activates mitogen-activated
protein kinases. Am J Physiol,
1997;272:G943-G953
14 O'Dwyer ST, Smith RJ, Hwang TL, Wilmore DW. Maintenance of
small bowel mucosa with glutamine-enriched
parenteral
nutrition. JPEN, 1989;13:579-585
15 Li J, Langkamp-Henken B, Suzuki K, Stahlgren LH. Glutamine
prevents parenteral nutrition-induced increases in
intestinal
permeability. JPEN, 1994;18:303-307
16 Platell C, McCauley R, McCulloch R, Hall J. The influence
of parenteral glutamine and branched-chain amino acids on
total
parenteral nutrition-induced atrophy of the gut. JPEN,
1993;17:348-354
17 Klimberg VS, Souba WW, Dolson DJ, Salloum RM, Hautamaki RD,
Plumley DA, Mendenhall WM, Bova FJ, Khan SR,
Hackett
RL, Bland KI, Copeland III EM.
Prophylactic glutamine protects the intestinal mucosa from radiation
injury.
Cancer,
1990;66:62-68
18 Fox AD, Kripke SA, De Paula J, Berman JM, Settle RG,
Rombeau JL. Effect of a glutamine-supplemented enteral diet
on
methotrexate-induced enterocolitis. JPEN, 1988;12:325-331
19 Tamada H, Nezu R, Matsuo Y, Imamura I, Takagi Y, Okada A.
Alanyl glutamine-enriched total parenteral nutrition
restores
intestinal adaptation after either proximal or distal massive
resection in rats. JPEN, 1993;17:236-242
20 Desjeux JF, Nath SK, Taminian J. Organic substrate and
electrolyte solutions for oral rehydration in diarrhea. Annu Rev
Nutr,
1994;14:321-342
21 Vanderhoof JA, Blackwood DJ, Mohammadpour H, Park JHY.
Effects of oral supplementation of glutamine on small
intestinal
mucosal mass following resection. J Am Coll Nutr,
1992;11:223-227
22 Michail S, Mohammadpour H, Park JHY, Vanderhoof JA. Effect
of glutamine-supplemented elemental diet on mucosal
adaptation
following bowel resection in rats. J Pediatr Gastroenterol Nutr,
1995;21:394-398
23 Wiren ME, Permert J, Skullman SP, Wang F, Larsson J. No
differences in mucosal adaptive growth one week after
intestinal
resection in rats given enteral glutamine supplementation or
deprived of glutamine. Eur J Surg,
1996;162:489-498
24 Alavi K, Kato Y, Yu D, Schwartz MZ. Enteral glutamine does
not enhance the effects of hepatocyte growth factor in short
bowel
syndrome. J Pediatr Surg, 1998;33:1666-1669
25 Yang H, Larsson J, Permert J, Braaf Y, Wiren M. No effect
of bolus glutamine supplementation on the postresectional
adaptation
of small bowel mucosa in rats receiving chow ad libitum. Dig
Surg, 2000;17:256-260
26 Smith RJ. Glutamine metabolism and its physiologic
importance. JPEN, 1990;14:40S-44S
27 Ko TC, Beauchamp RD, Townsend CM, Thompson JC. Glutamine is
essential for epidermal growth factor-stimulated
intestinal
cell proliferation. Surgery, 1993;114:147-154
28 Van Der Hulst RRWJ, Von Meyenfeldt MF, Deutz NEP,
Stockbrugger RW, Soeters PB. The effect of glutamine
administration
on intestinal glutamine content. J Surg Res, 1995;61:30-34
29 Heel KA, Kong SE, McCauley RD, Erber WN, Hall JC. The
effect of minimum luminal nutrition on mucosal cellularity and
immunity
of the gut. J Gastroenterol Hepatol, 1998;13:1015-1019
30 Bond JH, Currier BE, Buchwald H, Levitt MD. Colonic
conservation of malabsorbed carbohydrate. Gastroenterology,
1980;78:444-447
31 Nordgaard I, Hansen BS, Mortensen PB. Colon as a digestive
organ in patients with short bowel syndrome. Lancet,
1994;343:373-376
32 Koruda MJ, Rolandelli RH, Settle RG, Saul SH, Rombeau JL.
The effect of a pectin-supplemented elemental diet on
intestinal
adaptation to massive small bowel resection. JPEN, 1986;10:343-350
33 Roth JA, Frankel WL, Zhang W, Klurfeld DM, Rombeau JL.
Pectin improves colonic function in rat short bowel syndrome.
J
Surg Res, 1995;58:240-246
34 Michail S, Mohammadpour M, Park JH, Vanderhoof JA.
Soy-polysaccharide-supplemented soy formula enhances
mucosal
disaccharidase levels following massive small intestinal resection
in rats. J Pediatr Gastroenterol N
utr,1997;24:140-145
35 Kapadia SA, Raimundo AH, Grimble GK, Aimer P, Silk DBA.
Influence of three different fiber-supplemented enteral diets
on
bowel function and short-chain fatty acid production. JPEN,
1995;19:63-68
36 Bastie MJ, Balas D, Laval J, Senegas-Balas F, Bertrand C,
Frexinos J,Ribet A. Histological variations of jejunal and ileal
mucosa
on days 8 and 15 after
hypophysectomy in rat: morphometrical analysis in light and electron
microscopy.
Acta
Anat (Basel), 1982;112:321-337
37 Scow RO, Hagan SN. Effect of testosterone propionate and
growth hormone on growth and chemical composition of
muscle
and other tissues in hypophysectomized male rats.
Endocrinology, 1965;77:852-858
38 Ulshen MH, Dowling RH, Fuller CR, Zimmermann EM, Lund PK.
Enhanced growth of small bowel in transgenic mice
overexpressing
bovine growth hormone. Gastroenterology, 1993;104:973-980
39 Taylor B, Murphy GM, Dowling RH. Effect of food intake and
the pituitary on intestinal structure and function after small
bowel
resection in the rat. Gut, 1975;16:397-398
40 Shulman DI, Hu CS, Duckett G, Lavallee-Grey M. Effects of
short-term growth hormone therapy in rats undergoing 75%
small
intestinal resection. J Pediatr Gastroenterol Nutr, 1992;14:3-11
| |